Honasa Consumer to acquire 58% of Fluence Pharma for ₹135 crore, will create subsidiary

What Honasa Consumer announced

On 23 June 2026, the Board of Directors of Honasa Consumer Ltd approved the acquisition of a majority stake in Fluence Pharma Private Limited and the incorporation of a wholly‑owned subsidiary, Honasa Health Private Limited. The acquisition targets Fluence Pharma’s portfolio of condition‑specific over‑the‑counter (OTC) supplements marketed under the “Hair Fact”, “Skin Fact” and “Pro Fact” brands. The subsidiary will focus on business‑to‑consumer (B2C) operations for nutraceutical products.

Details of the Fluence Pharma acquisition

• Stake and valuation: Honasa will purchase a 58% equity stake in Fluence Pharma via a secondary purchase at an implied enterprise value of approximately ₹135 crore. The transaction is subject to standard closing adjustments and the satisfaction of stipulated conditions precedent.
• Future tranche: The Board also approved a plan to acquire the remaining 42% equity in two additional tranches over the next 5‑7 years. The timing of these tranches will be aligned with the completion of the initial 58% purchase and any further regulatory or contractual requirements.
• Transaction structure: The acquisition will be executed through a secondary share purchase from existing shareholders of Fluence Pharma. No cash infusion into Fluence Pharma’s operations is disclosed; the purchase price reflects the value of the equity being transferred.
• Regulatory filing: The announcement was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the relevant details have been filed with both the NSE and BSE.

Incorporation of Honasa Health Private Limited

Honasa Health Private Limited will be a wholly‑owned subsidiary of Honasa Consumer Ltd. Its mandate is to manage the B2C distribution of nutraceutical products, leveraging the newly acquired Fluence Pharma brands and Honasa’s existing e‑commerce capabilities. The subsidiary will operate from Honasa’s corporate office in Gurugram and will be responsible for product development, marketing, and direct sales to consumers.

Key facts at a glance

Why this matters for investors

• Strategic expansion: The acquisition gives Honasa immediate access to a portfolio of OTC supplements that complement its existing beauty‑and‑personal‑care offerings, potentially broadening its addressable market in the fast‑growing nutraceutical segment.
• Capital allocation: The initial outlay of roughly ₹135 crore is a material, but not overwhelming, commitment relative to Honasa’s market capitalisation. Future tranche payments are spread over several years, reducing short‑term cash pressure.
• Corporate structure: By housing the nutraceutical operations in a separate legal entity, Honasa can isolate financial performance, manage risk, and potentially attract dedicated investors or partners for the health‑focused business.
• Regulatory compliance: The filing under Regulation 30 ensures that shareholders receive timely information about a material transaction, satisfying SEBI’s disclosure norms.

Conclusion

Honasa Consumer Ltd’s board has cleared a ₹135 crore acquisition of a 58% stake in Fluence Pharma, with a roadmap to obtain full ownership over the next 5‑7 years. Simultaneously, the company will set up Honasa Health Private Ltd to run B2C nutraceutical sales. The transaction is now subject to customary closing conditions and regulatory approvals, after which Honasa will integrate the new brands into its expanding health‑and‑beauty ecosystem.